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attributable to the institution of Medicare Part D, a national
prescription drug beneﬁt program for the elderly instituted at the
end of 2005 in the United States. METHODS: We implemented
retrospective analyses of pharmacy claims of beneﬁciaries aged
67–79 years from 2005 to 2006, from a large pharmacy chain in
the United States. Subjects aged 61–63 were used a control group
in a differences-in-differences approach to account for trends not
related to Part D. The ﬁnal sample represented approximately
2.4 million unique beneﬁciaries aged 67–79. The main outcomes
are: 1) Changes in proportion of total days of therapy dispensed
as generics, and 2) changes in prescription utilization for each
therapeutic class. RESULTS: Prescription drug use by these ben-
eﬁciaries increased by 11% from 2005 to 2006. After adjustment
for secular trends and other potential confounders, utilization of
each therapeutic class was similar in 2005 and 2006. Small
increases in drug utilization occurred for several drug classes,
ranging from 0.66 pill days (0.46%) for users of nonsteroidal
anti-inﬂammatories (NSAIDs) to 4.64 pill days (1.78%) for users
of angiotensin-converting enzyme (ACE) inhibitors. Decreases
occurred for anti-diabetic drugs (–2.06 pill days, –0.58%), beta-
blockers (–1.24, –0.49%), and benzodiazepines (–5.96 pill days,
–3.57%). Overall, beneﬁciaries were slightly less likely to ﬁll
prescriptions for generic drugs vs. brand-name drugs in 2006
compared to 2005 (OR 0.98, 95% CI 0.97–0.98). CONCLU-
SION: Small increases in prescription drug utilization occurred
across numerous drug classes for these Medicare seniors follow-
ing the implementation of the Medicare Part D Prescription
Beneﬁt, while overall market share by drug class did not change
signiﬁcantly. Further analyses are needed to explore the degree to
which these changes reﬂect moral hazard versus beneﬁcial expan-
sions of coverage.
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OBJECTIVES: To quantify and characterize economic-content
in pharmaceutical advertisements, and its supporting evidence,
in leading American medical journals from 1990–2006.
METHODS: Two researchers reviewed all pharmaceutical adver-
tisements in three leading general medical (New England Journal
of Medicine, JAMA, and Annals of Internal Medicine) and spe-
cialty journals (Circulation, Gastroenterology, Neurology) in
three speciﬁed months each year for 2000 through 2006. Using a
standardized data collection form, we investigated economic
claims (e.g., ads using the words “value”, “price”, “savings”,
“hospitalization,” etc.), as well as the supporting evidence. This
work builds upon our previous research of economic claims from
1990–1999, adding new data and content. RESULTS: We
reviewed 3,516 pharmaceutical advertisements (2,144 from
1990–1999 and 1372 from 2000–2006). Economic content
occurred in 11.1% of ads in the 1990s, and 7.6% of ads in
2000–2006 (p = 0.0007). From 1997 to 2002, economic adver-
tisements declined (p < 0.0001), and increased again from 2003–
2006 (p = 0.0006), with a peak in 1997 at 16.2% and a nadir of
3.9% in 2002. Economic claims appeared with similar frequency
in the specialty journal ads across time periods (1990s: 8.6% vs.
2000–2006: 8.5%; p = 0.91), but declined in the general medical
journal ads (1990s: 13.0% vs. 2000–2006: 6.4%; p < 0.0001).
The presence of supporting evidence for economic claims was
similar in the 1990s and 2000s (63.7% vs. 61.5%, p = 0.70), but
over time derived less from the Red Book (1990s: 38.7% vs.
2000–2006: 15.6%) and average wholesale price listings (1990s:
51.1% vs. 2000–2006: 6.3%) and more from data on ﬁle (1990s:
9.5% vs. 2000–2006: 29.7%) and published studies (1990s:
6.6% vs. 2000–2006: 23.4%). From 2000–06, a small number of
ads mentioned patient compliance (2.6%) or persistence (2.0%).
CONCLUSION: Drug companies continue to promote health
economic messages in medical journal advertisements. Mention
of supporting evidence underlying economic claims has not
changed over time, though more ads reference published studies.
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OBJECTIVES: To evaluate the impact of anti-tumor necrosis
factor (anti-TNF) therapy on real world health care resource
utilization in patients with immune-mediated inﬂammatory dis-
eases (IMIDs). METHODS: Three groups of patients were iden-
tiﬁed using claims data from Blue Cross Blue Shield health plans:
IMID (rheumatoid arthritis, ankylosing spondylitis, Crohn’s
disease, psoriatic arthritis, psoriasis or ulcerative colitis) patients
receiving anti-TNF therapy between January 1, 2003 and June
30, 2005 (Group 1); IMID controls without anti-TNF therapy
(Group 2); and non-IMID controls (Group 3). The groups were
matched for gender, age and geographic region in a 3:1 ratio. All
patients had > = 6 months continuous plan enrollment before
and > = 12 months after the index date. Health care resource
utilizations per patient per month (PPPM) were calculated for the
6-month pre- and 12-month post-index periods. Differences from
baseline were compared among three groups. RESULTS: After
matching, 27,006 patients (3,970 Group 1; 11,718 Group 2; and
11,318 Group 3) were analyzed. Of these, 61% were female and
the average age was 46 years. Group 1 had higher pre-index
PPPM resource utilization for all categories than the 2 control
groups. However, compared with pre-index utilization, all post-
index resource utilization categories, except emergency room
visits, showed a signiﬁcant decrease for Group 1 that was not
consistently observed for controls. Inpatient admissions were
reduced in Group 1 (-16.28%), versus no change in Group 2,
and +4.17% for Group 3. Physician visits were reduced in Group
1 (–5.11%) versus +2.73% in Group 2, and +6.24% for Group
3. Non-anti-TNF prescriptions were reduced in Group 1
(-6.70%) versus +6.75% in Group 2, and +8.02% for Group 3.
CONCLUSION: Anti-TNF therapy appears to be associated
with a decrease in health care resource utilization. Additional
analyses to determine the effectiveness of anti-TNF therapies in
patients with IMIDs through clinical, economic, and humanistic
assessments are recommended.
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OBJECTIVES: A pharmacoeconomic analysis was performed to
determine the cost implications of providing rituximab (RTX, a
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